NfL, a single biomarker in the blood, can accurately predict the presence of underlying neurodegenerative disorders, such as FTD and ALS, in people with cognitive problems.
In Parkinson's disease, alpha-synuclein binds to LC3B. Normally, LC3B causes misfolded proteins to become degraded, but in the case of Parkinson's, LC3B becomes trapped in protein aggregates and becomes inactive.
A rare genetic mutation interferes with dopamine transporters in the brain, causing Parkinson's-like symptoms in children.
A new study reveals a potential link between REM sleep behavior disorder and an increased risk of developing Parkinson's disease. Researchers say the sleep disorder alters cerebral blood flow, leading to a lack of oxygen in brain tissue. This, in the long term, may increase Parkinson's risk.
A new gel that contains levodopa can adhere to nasal tissue. The gel releases levodopa directly into the blood and brain. Researchers say the preliminary data reveals the gel has proven to be effective in animal models.
Researchers have identified a layer of genetic material involved in controlling the production of tau in the brain. The material is part of a larger family of non-coding genes that regulate and control other brain proteins associated with neurodegenerative disorders, such as Alzheimer's disease, Parkinson's, and PSP. The findings could lead to the development of new therapeutics to treat a range of neurodegenerative disorders.
Researchers have successfully recorded brain signatures of movement symptoms and deep brain stimulation of Parkinson's patients in real time. The findings could lay the groundwork for personalize therapies for those with the neurodegenerative disease.
Study finds evidence of inflammation in the blood of patients during the early stages of Parkinson's disease. The findings support the theory that inflammation is a driver of the neurodegenerative disorder. The effect was most noticed in women with Parkinson's.